Three-Month Delay in US for Bupropion/Naltrexone for Obesity Three-Month Delay in US for Bupropion/Naltrexone for Obesity

The expected decision on bupropion/naltrexone for obesity has not materialized. Instead, the FDA has extended the review time by 3 months, with a decision now due in September. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news